In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement

Executive Summary

The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

You may also be interested in...



Momenta And Sandoz Pay $120m To Settle Enoxaparin Suit

Momenta and Sandoz must hand over $120m between them to a range of enoxaparin purchasers following final approval of a settlement agreement resolving claims the pair unfairly conspired to block further generic competition in the US to Sanofi’s Lovenox blood-thinner.

Sandoz, Momenta And Amphastar Settle US Enoxaparin Litigation

Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.

Momenta and Sandoz fail on US enoxaparin

Momenta and Sandoz face the prospect of paying treble damages to Amphastar over allegations the two firms “restricted trade and prevented competition in the manufacture and sale of generic enoxaparin” in the US, after a district judge denied Momenta’s bid to dismiss the US-based specialty company’s antitrust lawsuit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel